Literature DB >> 10895815

Myxoid leiomyosarcoma of soft tissue, an underrecognized variant.

B P Rubin1, C D Fletcher.   

Abstract

Myxoid leiomyosarcoma is an uncommon tumor which, although previously well described in the uterus, is recognized to a lesser extent at other sites. We describe 18 cases of soft tissue leiomyosarcoma in which myxoid stroma occupied >50% of the tissue examined. Patients ranged in age from 22 to 84 years old (median, 57.5 yrs) and female patients outnumbered male patients 14 to 4. Tumor locations included the limbs (6 cases), female external genitalia (4 cases), head and neck region (3 cases), chest (2 cases), nipple, paratesticular soft tissue, and perineum (one case each). The tumors had a grossly gelatinous appearance and adopted three major histologic architectures: fascicular, reticular/microcystic, and "myxofibrosarcoma-like." The tumor cells were predominantly spindled in all cases with typical features of smooth muscle differentiation; there was a mixture of spindle and epithelioid cells in one case. No cases with pure epithelioid cytology were seen. All tumors displayed immunoreactivity for smooth muscle markers (smooth muscle actin 16/17, desmin 8/18) and, in addition, four cases were positive for keratin CAM 5.2 and three for epithelial membrane antigen. The tumors had a tendency to be morphologically lower grade (9 tumors were grade I, 8 were grade II, and only 1 was grade III). Follow up was available in 13 patients with a duration of 8 months to 41 years (median, 39 mos), and revealed local recurrences (often repeated) in five cases and metastases in two cases. There were three tumor-related deaths, of which two were the result of uncontrolled local disease. The differential diagnosis of myxoid leiomyosarcoma is broad and encompasses both benign and malignant lesions. Accurate diagnosis is critical because therapies may differ widely for entities in the differential diagnosis of myxoid leiomyosarcoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10895815     DOI: 10.1097/00000478-200007000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Primary intravascular myxoid leiomyosarcoma of the femoral vein presenting clinically as deep vein thrombosis: a case report.

Authors:  Manish Mani Subramaniam; Miguel Martinez-Rodriguez; Samuel Navarro; Jorge Guijarro Rosaleny; Antonio Liombart Bosch
Journal:  Virchows Arch       Date:  2007-02       Impact factor: 4.064

2.  Atypical (bizarre) leiomyoma of the nasal cavity with prominent myxoid change.

Authors:  A Vincenzi; G Rossi; D Monzani; L Longo; F Rivasi
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

3.  Recurrent high-grade leiomyosarcoma with heterologous osteosarcomatous differentiation.

Authors:  Florian Grabellus; Sien-Yi Sheu; Boris Schmidt; Michael Flasshove; Cornelius Kuhnen; Steffen Ruchholtz; Georg Taeger; Kurt Werner Schmid
Journal:  Virchows Arch       Date:  2005-10-14       Impact factor: 4.064

4.  Hepatic Myxoid Leiomyoma: A Very Rare Tumor.

Authors:  João Fraga; Rui Caetano Oliveira; Luigi Terracciano; Mário Rui Silva; Maria Augusta Cipriano
Journal:  GE Port J Gastroenterol       Date:  2019-12-18

5.  Presumptive metastatic leiomyosarcoma in a feedlot steer.

Authors:  Fernando J Guardado; Kamal Gabadage; Andrew L Allen
Journal:  Can Vet J       Date:  2022-08       Impact factor: 1.075

Review 6.  Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist?

Authors:  Stefan M Willems; Malgorzata Wiweger; J Frans Graadt van Roggen; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-08-25       Impact factor: 4.064

Review 7.  Myxoid solitary fibrous tumor: a clinicopathologic study of three cases.

Authors:  Sean K Lau; Lawrence M Weiss; Peiguo G Chu
Journal:  Virchows Arch       Date:  2009-01-06       Impact factor: 4.064

8.  Surgery Treatment Improved the Overall Survival Rate in Locoregional Myxoid Leiomyosarcoma than Other Myxosarcomas in the United States.

Authors:  Marwan Almoiliqy; Abdullah Al-Danakh; Mohammed Safi; Mohammed Alradhi; Mahmoud Al-Azab; Salah Adlat; Wanhai Zhou; Aiman Saleh A Mohammed; Ahmed Al-Maamari
Journal:  Oxid Med Cell Longev       Date:  2021-04-30       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.